HomeCompareUFAB vs PFE

UFAB vs PFE: Dividend Comparison 2026

UFAB yields 119.33% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $1.5K in total portfolio value· pulled ahead in Year 10
10 years
UFAB
UFAB
● Live price
119.33%
Share price
$0.17
Annual div
$0.20
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$48.1K
Annual income
$28.47
Full UFAB calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — UFAB vs PFE

📍 PFE pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodUFABPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, UFAB + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
UFAB pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

UFAB
Annual income on $10K today (after 15% tax)
$10,143.20/yr
After 10yr DRIP, annual income (after tax)
$24.20/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $22,295.70/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of UFAB + PFE for your $10,000?

UFAB: 50%PFE: 50%
100% PFE50/50100% UFAB
Portfolio after 10yr
$48.8K
Annual income
$13,143.60/yr
Blended yield
26.92%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

UFAB
Analyst Ratings
3
Buy
1
Hold
Consensus: Buy
Altman Z
0.5
Piotroski
4/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

UFAB buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricUFABPFE
Forward yield119.33%6.13%
Annual dividend / share$0.20$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%13.2%
Portfolio after 10y$48.1K$49.6K
Annual income after 10y$28.47$26,258.71
Total dividends collected$16.9K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyHold

Year-by-year: UFAB vs PFE ($10,000, DRIP)

YearUFAB PortfolioUFAB Income/yrPFE PortfolioPFE Income/yrGap
1$16,667$5,966.59$9,153$693.39+$7.5KUFAB
2$22,480$4,646.85$8,593$849.25+$13.9KUFAB
3$26,983$2,928.85$8,336$1,066.78+$18.6KUFAB
4$30,514$1,642.74$8,437$1,384.80+$22.1KUFAB
5$33,518$868.10$9,013$1,875.40+$24.5KUFAB
6$36,310$445.59$10,306$2,680.72+$26.0KUFAB
7$39,077$225.56$12,820$4,101.38+$26.3KUFAB
8$41,926$113.44$17,673$6,826.70+$24.3KUFAB
9$44,918$56.87$27,543$12,591.86+$17.4KUFAB
10← crossover$48,091$28.47$49,560$26,258.71$1.5KPFE

UFAB vs PFE: Complete Analysis 2026

UFABStock

Unique Fabricating, Inc. engineers and manufactures multi-material foam, rubber, and plastic components utilized in noise, vibration, harshness, acoustical management, water and air sealing, decorative, and other functional applications. The company offers die cut products comprising noise, vibration, and harshness (NVH) pads for lining internal panels; buzz, squeak, and rattle felts and flocks; foam blocks; and gaskets, seals, insulation, and attachment tapes. In addition, it offers thermoformed molded products, including TwinShape foam air ducts; heating, ventilation, and air conditioning (HVAC) evaporator liners; and console bin mats, fender insulators, and molded seat undercovers. Further, the company provides fusion molded products comprising exterior mirror seals, cowl-to-hood seals, and cowl-to-fender seals, as well as other NVH management and sealing applications, such as fillers, spacers, and gaskets; and reaction injection molded products, including rigid foam, integral-skin, viscoelastic, energy absorbing, and high resilience. Unique Fabricating, Inc. sells its products to transportation, appliance, medical, and consumer off-road markets in North America. The company was founded in 1975 and is headquartered in Auburn Hills, Michigan.

Full UFAB Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this UFAB vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

UFAB vs SCHDUFAB vs JEPIUFAB vs OUFAB vs KOUFAB vs MAINUFAB vs JNJUFAB vs MRKUFAB vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.